Immunovant (IMVT) Accumulated Expenses (2018 - 2026)

Immunovant's Accumulated Expenses history runs 9 years deep, the most recent figure standing at $96.6 million for Q1 2026.

• Quarterly Accumulated Expenses rose 90.42% year-over-year to $96.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.6 million (up 90.42% YoY) and the FY2026 annual result came in at $96.6 million, up 90.42% from the prior year.
• Accumulated Expenses was $96.6 million for Q1 2026 at Immunovant, up from $57.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $96.6 million in Q1 2026 and bottomed at $19.0 million in Q2 2022.
• A 5-year average of $40.8 million and a median of $40.4 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses retreated 17.16% — and 2026, when it jumped 90.42%.
• Immunovant's Accumulated Expenses stood at $26.0 million in 2022, then grew by 7.05% to $27.9 million in 2023, then jumped by 73.84% to $48.5 million in 2024, then rose by 18.91% to $57.6 million in 2025, then jumped by 67.65% to $96.6 million in 2026.
• Business Quant data shows IMVT's Accumulated Expenses at $96.6 million in Q1 2026, $57.6 million in Q4 2025, and $56.3 million in Q3 2025.